Clinical trials: PET-CT
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who…
- Trial name
- NCT02384382
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Neuroendocrine Neoplasms
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
The purpose of this study was to evaluate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in…
- Trial name
- NCT06240741
- Testing
- [68Ga]Ga-DOTA-TATE, 68Ge/68Ga Generator
- Where
- 8 sites in Japan
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Prosthetic Joint Infections
[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint
This protocol will evaluate the sensitivity and specificity of [124I]FIAU as a diagnostic imaging agent for the detection of prosthetic joint infections in patients.
- Trial name
- PJI (NCT01705496)
- Testing
- [124I]FIAU
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- BioMed Valley Discoveries, Inc
Subjects With Clinical Indication for PET/CT
Clinical Evaluation of an Integrated PET/MRI System
The investigational PET/MRI scanner, including attenuation correction method, is capable of producing diagnostic quality images and appropriate device functionality per user feedback.
- Trial name
- PET/MR_ZURICH (NCT02071706)
- Testing
- PET/MRI system
- Where
- Switzerland
- Volunteers
- 62 people
- Sponsor
- GE Healthcare
Metastatic Prostate Cancer
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
This Phase 3 study will target approximately 100 men over age 18 who have a biochemical relapse or other evidence of relapse of prostate cancer after primary treatment. The purpose of this study is to: A.
- Trial name
- NCT02260817
- Testing
- 11C-choline Injection
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Global Isotopes, LLC d/b/a Zevacor Molecular
Prostate Cancer
A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer
To investigate the utility of fluciclovine F 18 for evaluation for metastatic disease in men undergoing laser focal therapy of prostate cancer and the impact on inclusion for a focal therapy cohort.
- Trial name
- NCT03373006
- Testing
- Axumin PET/CT
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- HALO Diagnostics
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 in BCR
The current study aimed at evaluating the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of Prostate specific membrane antigen (PSMA) positivity in patients diagnosed of biochemical…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Recurrence
- Trial name
- GuidePath (NCT04838613)
- Testing
- [18F]CTT1057, [68Ga]Ga-PSMA-11
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
This prospective study will enroll up to 330 men with PSA-persistent or PSA-recurrent prostate cancer after curative-intent primary therapy and negative or equivocal findings on standard-of-care imaging.
- Trial name
- LOCATE (NCT02680041)
- Testing
- 18F-fluciclovine PET CT
- Where
- 17 sites in United States
- Volunteers
- 221 people
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer, Prostate Adenocarcinoma
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Trial name
- CONDOR (NCT03739684)
- Testing
- 18F-DCFPyL, PET/CT Imaging
- Where
- 14 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Indication for a PET CT Exam
Development of an Integrated Positron Emission Tomography/Magnetic Resonance (PET/MR) System, Accessories and Components
The PET/MR device components and accessories are under development in order to optimize, validate and improve the design including improving the quality of images.
- Trial name
- NCT01992354
- Testing
- PET MR Device
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
- Trial name
- 89ZR-TLX250 (NCT03849118)
- Testing
- 89Zr-girentuximab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 300 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Autoimmune Diseases
A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts
This is a pilot imaging study to determine whether molecular imaging with 18^F fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), 11^C-Methionine (MET) PET/CT, and salivary gland magnetic…
- Trial name
- NCT02899377
- Testing
- 18F-FDG PET/CT Imaging, 11C-MET PET/CT Imaging, MRI Imaging with intravenous contrast with gadoterate meglumine
- Where
- 4 sites in United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
- Trial name
- NCT02888080
- Testing
- ACZ885
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Liver Metastases, Colorectal Carcinoma
An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
- Trial name
- NCT03029988
- Testing
- Tilmanocept (Technetium Tc 99m tilmanocept Injection), SPECT/CT Imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Navidea Biopharmaceuticals
Graft Versus Host Disease
Detection of Graft Versus Host Disease With [18F]F-AraG
This is a single-center imaging study to determine utility of in vivo imaging with [18F]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy…
- Trial name
- NCT03367962
- Testing
- [18F]F-Ara-G
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- CellSight Technologies, Inc.
Any Condition With a Clinical Indication for PET/CT Exam
Comparison of 18F FDG PET/CT TO PET MRI
The objective of this study is to gather image and associated data to of a pre-market PET/MRI scanner and to use the data for regulatory submission and future product development and marketing.
- Trial name
- PET/MR US (NCT01986985)
- Testing
- PET/MRI system
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- GE Healthcare
Diabetic Foot Infection
[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection
This protocol will evaluate the sensitivity and specificity of [124I]FIAU as a diagnostic imaging agent for the detection of osteomyelitis in patients with diabetic foot infection.
- Trial name
- NCT01764919
- Testing
- [124I]FIAU
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- BioMed Valley Discoveries, Inc
Non-Small Cell Lung Cancer
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
This is a single-arm, open-label, multicenter, international pilot study to evaluate changes that occur in 2-deoxy-2-[18F]fluoro-D-glucose (FDG)- and 3'-deoxy-3'-[18F]fluorothymidine(FLT)-PET (Positron Emission Tomography)…
- Trial name
- NCT00453362
- Testing
- 2-deoxy-2-[18F]fluoro-D-glucose (FDG), 3'-deoxy-3'-[18F]fluorothymidine (FLT), erlotinib HCl
- Volunteers
- 88 people
- Sponsor
- Genentech, Inc.
Prostate Cancer
68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer
This will be an open-labelled, single centre study in the UK. The study group will include 60 patients with three groups of patients being studied.
- Trial name
- PRONOUNCED (NCT03617588)
- Testing
- Gallium-68 THP-PSMA
- Where
- 4 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Theragnostics Ltd
Carotid Stenosis
[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis
This trial will be the first trial for the Investigation Product (IP), [F-18]RGD-K5 for carotid plaque imaging and will be conducted as a Phase II trial since this compound has already been tested in humans for phase I and phase…
- Trial name
- NCT01602471
- Testing
- [F-18]RDG-K5
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Siemens Molecular Imaging